|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-5-14
|
|
pubmed:abstractText |
Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Ergocalciferols,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Matrix Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Inflammation Mediators,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Calcitriol,
http://linkedlifedata.com/resource/pubmed/chemical/Vitamins,
http://linkedlifedata.com/resource/pubmed/chemical/paricalcitol
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1523-1755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
943-5
|
|
pubmed:meshHeading |
pubmed-meshheading:20467430-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:20467430-Animals,
pubmed-meshheading:20467430-Biological Markers,
pubmed-meshheading:20467430-Blood Urea Nitrogen,
pubmed-meshheading:20467430-Creatinine,
pubmed-meshheading:20467430-Diabetes Mellitus, Type 2,
pubmed-meshheading:20467430-Diabetic Nephropathies,
pubmed-meshheading:20467430-Disease Progression,
pubmed-meshheading:20467430-Drug Synergism,
pubmed-meshheading:20467430-Drug Therapy, Combination,
pubmed-meshheading:20467430-Ergocalciferols,
pubmed-meshheading:20467430-Extracellular Matrix Proteins,
pubmed-meshheading:20467430-Humans,
pubmed-meshheading:20467430-Inflammation Mediators,
pubmed-meshheading:20467430-Kidney Glomerulus,
pubmed-meshheading:20467430-Losartan,
pubmed-meshheading:20467430-Mice,
pubmed-meshheading:20467430-Receptors, Calcitriol,
pubmed-meshheading:20467430-Renin-Angiotensin System,
pubmed-meshheading:20467430-Vitamins
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
|
|
pubmed:affiliation |
Indiana University School of Medicine and Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana 46202, USA. ragarwal@iupui.edu
|
|
pubmed:publicationType |
Journal Article,
Comment,
Research Support, Non-U.S. Gov't
|
